Comparing the current results to its competitors, Vincerx Pharma Inc reported Revenue decrease in the 1 quarter 2025 year on year by 0 %, slower than the combined decrease of the VINC's competitors by -5.24 %, recorded in the same quarter.
Vincerx Pharma Inc 's Comment on Competition and Industry Peers
The biotechnology industry, particularly the oncology sector, is highly competitive and characterized by rapid technological advancements and a strong focus on intellectual property. Competitors include specialty pharmaceutical and biotechnology companies, research organizations, academic institutions, and governmental agencies. Product candidates face competition from existing therapies as well as emerging treatments such as small molecules, biologics, bioconjugates, and cell or gene therapies. The company’s bioconjugation product candidates and VersAptx platform are positioned as differentiated; however, many companies invest in bioconjugate innovation targeting similar indications. Notable competitors include AbbVie Inc., ADC Therapeutics SA, Astellas Pharma Inc., AstraZeneca PLC, Bicycle Therapeutics plc, Bristol-Myers Squibb Company, CytomX Therapeutics, Inc., Daiichi Sankyo Company, Limited, Duality Biologics Co. Ltd., Eli Lilly and Company, Genentech, Inc., Gilead Sciences, Inc., GSK plc, Iksuda Therapeutics Ltd, Innovent Biologics, Inc., ImmunoGen, Inc. (acquired by AbbVie, Inc.), Immunomedics, Inc., Johnson & Johnson Inc., Klus Pharma, Inc., LigoChem Biosciences, Inc., MacroGenics, Inc., Merck & Co., Inc., Merck KGaA, Mersana Therapeutics Inc., Novartis International AG, ProfoundBio Inc., Pyxis (which acquired Pfizer), Cyclacel Pharmaceuticals Inc., Kronos Bio, Inc., Prelude Therapeutics Inc., SELLAS Life Sciences Group, Inc., and Sumitomo Dainippon Pharma Co., Ltd. These competitors may develop CDK9 inhibitor programs and other related therapies that could compete with the company’s products. To remain competitive, the company’s products must demonstrate superior efficacy, safety, and tolerability.
October 7, 2024
Vincerx Pharma s Promising Advances: VIP943 Shows Initial Clinical Success and Future Potential in Cancer TreatmentIn a landscape where innovative therapies remain crucial to improving patient outcomes, Vincerx Pharma has charted a noteworthy path with its investigational therapies, particularly VIP943. Recent announcements have underscored the potential of this novel CD123-targeted antibody-drug conjugate (ADC) developed through Vincerx s proprietary VersAptx platform, emphasizing both positive initial clinical outcomes and ongoing commitment to pipeline advancements.During the ongoing Phase 1 dose-escalation study for VIP943, Vincerx has reported encouraging results, including its safety profile, tolerabi...
January 7, 2024
Vincerx Pharma s Enitociclib Shows Promise in Combating Lymphoma, According to National Institutes of Health (NIH) ReportVincerx Pharma, a leading biopharmaceutical company, recently announced the remarkable clinical efficacy of Enitociclib in combination with Venetoclax and Prednisone in lymphoma patients. The findings were reported by investigators from the prestigious National Institutes of Health (NIH), who are conducting an ongoing dose-escalation trial for this innovative treatment approach.In the trial, the researchers observed two partial responses (PR) in three patients with peripheral T-cell lymphoma (PTCL) and one PR in two patients with double-hit diffuse large B-cell lymphoma (DH-DLBCL). These ...
Xbiotech Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutic antibodies. They seek to address unmet medical needs by leveraging their proprietary True Human antibody technology.
The business model of Innovation1 Biotech Inc involves developing and commercializing innovative biotechnological products and solutions for various industries. The company focuses on research, development, and manufacturing, aiming to provide cutting-edge biotech solutions that meet the needs of diverse markets.
Matinas Biopharma Holdings Inc operates as a clinical-stage biopharmaceutical company. Their business model centers around developing therapeutics through the utilization of lipid nano-crystal (LNC) platform technologies. These technologies enable the effective delivery of drugs to improve patient outcomes in various diseases and conditions such as fungal infections, viral infections, and cancer.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Mineralys Therapeutics Inc is a biotechnology company that follows the business model of developing and commercializing novel therapeutics for various diseases. They focus on discovering and advancing small molecule drugs based on innovative research approaches. Their business model is centered around conducting preclinical and clinical trials, obtaining regulatory approvals, and ultimately bringing their therapeutic products to market for improved patient outcomes.
Sources:
Vincerx Pharma Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Vincerx Pharma Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
